This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy (AlloRelapseMM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05675319
Recruitment Status : Recruiting
First Posted : January 9, 2023
Last Update Posted : April 25, 2023
Gemeinsamer Bundesausschuss (G-BA)
Staburo GmbH
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2028
Estimated Study Completion Date : March 2033